369.16
-7.70 (-2.04%)
| Previous Close | 376.86 |
| Open | 372.55 |
| Volume | 239,732 |
| Avg. Volume (3M) | 354,958 |
| Market Cap | 41,760,178,176 |
| Price / Earnings (TTM) | 66.16 |
| Price / Earnings (Forward) | 46.51 |
| Price / Sales | 6.76 |
| Price / Book | 7.85 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Profit Margin | -9.40% |
| Operating Margin (TTM) | 0.99% |
| Diluted EPS (TTM) | -3.69 |
| Quarterly Revenue Growth (YOY) | 48.60% |
| Total Debt/Equity (MRQ) | 28.49% |
| Current Ratio (MRQ) | 1.96 |
| Operating Cash Flow (TTM) | 212.02 M |
| Levered Free Cash Flow (TTM) | -120.68 M |
| Return on Assets (TTM) | -3.22% |
| Return on Equity (TTM) | -11.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | BeOne Medicines Ltd. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -5.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 4.0 |
| Average | 0.88 |
|
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company’s main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 17.31% |
| % Held by Institutions | 43.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Capital International, Inc./Ca/ | 30 Jun 2026 | 305,477 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| OYLER JOHN | - | 359.11 | -240,810 | -86,472,679 |
| Aggregate Net Quantity | -240,810 | |||
| Aggregate Net Value ($) | -86,472,679 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 359.11 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| OYLER JOHN | Officer | 12 Aug 2026 | Automatic sell (-) | 54,892 | 359.05 | 19,708,973 |
| OYLER JOHN | Officer | 11 Aug 2026 | Automatic sell (-) | 70,907 | 359.27 | 25,474,758 |
| OYLER JOHN | Officer | 10 Aug 2026 | Automatic sell (-) | 115,011 | 359.00 | 41,288,949 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |